Biologic therapy has become a cornerstone of treatment for moderate-to-severe psoriasis, atopic dermatitis and other inflammatory skin diseases, yet a persistent clinical question shadows every prescription: what to do when the patient carries a malignancy risk.

The topic — examined by Physician's Weekly under the headline "Using Biologics in Patients With Malignancy Risk" — sits at the intersection of two competing imperatives. On one side stands the demonstrated efficacy of biologics in clearing disease measured by validated endpoints such as PASI and EASI. On the other stands the caution embedded in every drug label and the history of immunosuppression oncology, where modulation of immune pathways has, in some contexts, impaired surveillance against malignant cells.

For dermatologists, the practical stakes are concrete. Patients with psoriasis have well-documented elevations in certain malignancies relative to the general population, a signal driven partly by disease-related inflammation, partly by concomitant immunosuppressants such as methotrexate or cyclosporine, and partly by surveillance bias. When such a patient needs a biologic, the clinician must decide whether to proceed, which agent to choose, and how to monitor.

The discussion of biologics and cancer risk in inflammatory disease has evolved considerably over the past two decades. Early concern focused heavily on TNF-alpha inhibitors, driven by case reports of lymphoma and by the theoretical rationale that tumor necrosis factor participates in immune surveillance. Subsequent registry data and meta-analyses softened those fears for most agents, though labels retain warnings and individual patient history still governs decisions.

Newer mechanisms complicate the picture further. IL-17 inhibitors, central to modern psoriasis care and capable of delivering PASI 90 and PASI 100 responses in pivotal trials, act on a pathway with documented roles in tumor biology. IL-23 inhibitors, now dominant in the psoriasis market, target a cytokine upstream of the IL-17 axis. IL-4 and IL-13 blockade underpins dupilumab, the biologic backbone of moderate-to-severe atopic dermatitis treatment. For each class, the question is whether sustained pathway inhibition changes cancer incidence — and for most, large datasets have been reassuring rather than alarming.

The harder cases are not statistical but individual. A patient with active or recent malignancy, a history of lymphoma, or premalignant lesions forces a risk-benefit calculation that no package insert resolves. Clinical practice generally follows several principles that emerge repeatedly in expert discussion of this question.

First, disease control itself matters to cancer risk. Chronic inflammation is not a neutral state, and inadequately treated inflammatory disease carries its own morbidity and possibly its own oncologic signal. Second, agent selection matters when risk stratifying: clinicians often express more caution with TNF inhibitors in patients with lymphoma history than with newer interleukin-targeted agents, reflecting the distribution of safety signals across the literature. Third, coordination with oncology is not optional — timing therapy around surgical treatment, radiation or systemic oncology regimens requires explicit communication between specialties.

Screening also changes. Patients starting biologics with elevated malignancy risk typically need age-appropriate cancer screening current before initiation, and dermatologists should document skin-cancer surveillance plans, since cutaneous malignancies remain among the most relevant concerns for long-term immunomodulated patients. Regular total-body skin examinations, attention to actinic damage, and coordination on management of any non-melanoma skin cancers diagnosed during therapy all fall within standard practice.

Shared decision-making anchors the entire process. Patients deserve a clear account of what the evidence does and does not show: large observational datasets have not demonstrated a consistent, clinically meaningful increase in malignancy attributable to most dermatology biologics, but rare signals, class differences and residual uncertainty are real. That conversation, documented, protects both patient and prescriber.

What the Physician's Weekly piece underscores is that "malignancy risk" is not a monolithic contraindication. It is a spectrum — from a remote family history to active metastatic disease — and the prescribing decision shifts accordingly along that spectrum.

For the field, the direction of travel is toward more, not less, biologic use in complicated patients, supported by accumulating real-world safety registries such as PSOLAR for psoriasis and analogous pharmacovigilance programs for atopic dermatitis agents. As those datasets mature and post-approval studies accumulate longer follow-up, expect sharper, mechanism-specific guidance on which agents can be prescribed with confidence in which oncologic contexts.